Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapeutics that seek to halt progression of fibrotic diseases — ultimately preserving organ function. Our lead product candidate, PLN-74809, is an orally available small molecule designed to be a selective inhibitor of αvβ1 and αvβ6, two integrins that play key roles in multiple fibrotic pathways. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). We are currently conducting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant’s second clinical stage product candidate, PLN-1474, is designed to be a small molecule selective inhibitor of αvβ1, targeting liver fibrosis associated with nonalcoholic steatohepatitis (NASH). PLN-1474 is a Phase 2-ready program following the successful completion of a Phase 1 study. Pliant is initiating a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition to clinical stage programs, Pliant currently has a preclinical program targeting muscular dystrophies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.